Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Efficacy of Androxal® in Improving Glycemic Control in Men With Secondary Hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and Type 2 Diabetes Mellitus With Sub-Optimum Treatment

NCT01191320 is registered in ClinicalTrials.gov with Repros Therapeutics Inc. as lead sponsor.

NCT NCT01191320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01191320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Efficacy of Androxal® in Improving Glycemic Control in Men With Secondary Hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and Type 2 Diabetes Mellitus With Sub-Optimum Treatment
Lead sponsor
Repros Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
December 31, 2011
Enrollment
102 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hypogonadism, type 2 diabetes mellitus